Harbor Investment Advisory’s Hepion Pharmaceuticals HEPA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-1
| Closed | – | – | 1195 |
|
|
2025
Q2 | $0 | Buy |
+1
| New | – | ﹤0.01% | 1196 |
|
|
2025
Q1 | – | Hold |
0
| – | – | – | 1186 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 1160 |
|
|
2024
Q3 | – | Hold |
0
| – | – | – | 1149 |
|
|
2024
Q2 | – | Hold |
0
| – | – | – | 1302 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 1326 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 1156 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 1181 |
|
|
2023
Q2 | – | Hold |
0
| – | – | – | 1335 |
|
|
2023
Q1 | – | Hold |
0
| – | – | – | 1323 |
|
|
2022
Q4 | – | Hold |
0
| – | – | – | 1360 |
|
|
2022
Q3 | – | Hold |
0
| – | – | – | 1348 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 1359 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 1353 |
|
|
2021
Q4 | – | Hold |
0
| – | – | – | 1324 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 1329 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 1279 |
|
|
2021
Q1 | – | Hold |
0
| – | – | – | 1280 |
|
|
2020
Q4 | – | Hold |
0
| – | – | – | 1214 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 1181 |
|
|
2020
Q2 | – | Hold |
0
| – | – | – | 1186 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 1086 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 901 |
|
Harbor Investment Advisory's HEPA Position: Q3 2025 in Review
Harbor Investment Advisory sold out of Hepion Pharmaceuticals (HEPA) in Q3 2025, closing a stake of 1 share.
Harbor Investment Advisory first reported a position in HEPA in Q2 2025 and held it in 1 quarter. The position peaked at $0 in Q2 2025. 1 fund tracked by Wall St. Rank holds HEPA as of Q3 2025.
- Harbor Investment Advisory reported no remaining Hepion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
- Harbor Investment Advisory sold 1 Hepion Pharmaceuticals share in Q3 2025.
- Harbor Investment Advisory first reported a position in Hepion Pharmaceuticals in Q2 2025 and held it in 1 quarter.
- Harbor Investment Advisory's Hepion Pharmaceuticals position peaked at $0 in Q2 2025.
- 1 fund tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q3 2025.
Based on Harbor Investment Advisory's 13F filing for Q3 2025, filed 27 Oct 2025.